Navigation Links
Sigma® Life Science Enters Genetically Modified Cell Market

ST. LOUIS, Sept. 2 /PRNewswire-FirstCall/ -- Sigma Life Science, the innovative biological products and research services business of Sigma-Aldrich® Corporation (Nasdaq: SIAL), today announced the global release of a pioneering range of engineered mammalian cell lines. This new product range combines Sigma's proprietary CompoZr zinc finger nuclease (ZFN) technology with the Company's extensive experience in gene silencing, to offer innovative tools for drug discovery, compound screening and fundamental research applications.

This new range of products includes immortalized cell lines for a broad spectrum of applications, each precisely engineered to help scientists answer specific biological questions. By exploiting the revolutionary genomic editing capabilities of ZFNs, Sigma's scientists can rapidly manufacture stable cell lines with precise, well characterized genetic manipulations. "CompoZr ZFN technology is a significant breakthrough for cell-based research. It enables scientists to generate precisely controlled additions, deletions and modifications to the genome of a living cell," said Dr. Supriya Shivakumar, Global Commercial Marketing Manager for Functional Genomics at Sigma Life Science. "Leveraging this innovative and powerful technology to develop ready-to-use, validated cell lines is part of Sigma's ongoing commitment to furthering our understanding of biology."

The program will use ZFNs to incorporate and develop cell lines with a variety of cellular markers expected to aid in compound screening studies and biochemical pathway analysis, as well as specific isogenic lines designed to advance colorectal and breast cancer research.  In addition, Sigma offers a custom cell line engineering service, creating bespoke cell lines to perfectly match a researcher's application. "At Sigma Life Science, we have both the advanced technologies and manufacturing expertise to produce high quality, reliable tools for life science research. By offering complete modified cell lines alongside our portfolio of advanced bioediting technologies, we can provide a complete range of solutions to help accelerate our customers' research," Dr. Shivakumar added.

For more information about Sigma Life Science's cell line products, visit

Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "engineered to help," "expected to aid," "accelerate" or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that the engineered mammalian cell lines will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of the products from the engineered mammalian cell lines will achieve any particular levels of revenue in the future. In particular, management's expectations regarding the engineered mammalian cell lines could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company's  leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company that is committed to enabling science to improve the quality of life. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. Sigma-Aldrich has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 7,600 employees providing excellent service worldwide. For more information about Sigma-Aldrich, please visit its award-winning website at

Sigma-Aldrich, Sigma and CompoZr are trademarks of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.

SOURCE Sigma-Aldrich
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpace Highlights Northern Californias Growing Life Science Region
2. Naurexs Novel Antidepressant GLYX-13 Recognized as One of Windhovers Top 10 Neuroscience Projects to Watch
3. Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC
4. West Michigan Launches $10 Million Early Stage Venture Fund to Support Life Science & Technology
5. TraceLink Partners with Patheon to Optimize Life Science Contract Manufacturing Performance
6. New resource examines questions about the role of nanoscience
7. Signum Biosciences Names Braham Shroot as Chief Executive Officer
8. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
9. Canadas Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing
10. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
11. BioSpace Showcases the Midwests Growing Life Science Region
Post Your Comments:
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) ... remaining 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) ... B Warrants") subject to the previously disclosed November ... 2015, which will result in the issuance of ... the issuance of such shares, there will be ...
(Date:11/24/2015)... ... 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions for ... Aregger to serve as Chief Operating Officer. , Having joined InSphero in ... and was promoted to Head of InSphero Diagnostics in 2014. There she ...
(Date:11/24/2015)... LOS ANGELES , Nov. 24, 2015 ... a biotechnology company focused on the discovery, development and ... Marban , Ph.D., Chief Executive Officer, is scheduled to ... December 1, 2015 at 10:50 a.m. EST, at The ... York City . . ...
(Date:11/24/2015)... and NEW YORK , November 24, 2015 ... by Bristol-Myers Squibb in a European ... Squibb Company in which the companies will work closely ... and other areas of unmet medical need. The collaboration is ... 5, the latest LSP fund. This is the first investment ...
Breaking Biology Technology:
(Date:11/12/2015)...   Growing need for low-cost, easy to ... paving the way for use of biochemical sensors ... in clinical, agricultural, environmental, food and defense applications. ... medical applications, however, their adoption is increasing in ... emphasis on improving product quality and growing need ...
(Date:11/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), the ... entry into the automotive market with a comprehensive and ... of consumer electronics human interface innovation. Synaptics, industry-leading touch ... the automotive industry and will be implemented in numerous ... , Japan , and ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
Breaking Biology News(10 mins):